Fresenius SE KGaA Future Growth

Future criteria checks 3/6

Fresenius SE KGaA's revenue is forecast to decline at 5.2% per annum while its annual earnings are expected to grow at 20.8% per year. EPS is expected to grow by 20.2% per annum. Return on equity is forecast to be 9.1% in 3 years.

Key information

20.8%

Earnings growth rate

20.2%

EPS growth rate

Healthcare earnings growth	24.7%
Revenue growth rate	-5.2%
Future return on equity	9.1%
Analyst coverage	Good
Last updated	26 Feb 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

BUL:FRE - Analysts future estimates and past financials data (EUR Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	25,591	2,064	1,817	3,084	8
12/31/2025	24,334	1,833	1,607	2,800	12
12/31/2024	23,130	1,455	1,416	2,629	11
12/31/2023	22,421	722	1,686	1,554	11
9/30/2023	41,599	941	2,584	4,593	N/A
6/30/2023	41,467	1,026	2,519	4,441	N/A
3/31/2023	41,345	1,305	2,312	4,272	N/A
12/31/2022	40,840	1,372	2,234	4,198	N/A
9/30/2022	25,828	1,444	2,723	4,123	N/A
6/30/2022	29,766	1,611	2,137	4,093	N/A
3/31/2022	38,256	1,796	2,503	4,527	N/A
12/31/2021	37,520	1,818	2,999	5,078	N/A
9/30/2021	36,858	1,729	2,487	4,719	N/A
6/30/2021	36,452	1,743	2,384	4,692	N/A
3/31/2021	36,126	1,683	4,043	6,323	N/A
12/31/2020	36,277	1,707	4,110	6,549	N/A
9/30/2020	36,284	1,812	3,979	6,445	N/A
6/30/2020	36,208	1,829	4,203	6,729	N/A
3/31/2020	36,049	1,889	2,243	4,852	N/A
12/31/2019	35,409	1,883	1,766	4,263	N/A
9/30/2019	34,933	1,884	1,797	4,170	N/A
6/30/2019	34,283	1,859	1,622	3,980	N/A
3/31/2019	33,904	2,040	1,500	3,795	N/A
12/31/2018	33,530	2,027	1,508	3,742	N/A
9/30/2018	33,390	2,022	1,510	3,665	N/A
6/30/2018	33,495	1,999	1,490	3,510	N/A
3/31/2018	33,645	1,797	1,795	3,697	N/A
12/31/2017	33,886	1,814	2,088	3,937	N/A
9/30/2017	33,011	1,745	2,411	4,133	N/A
6/30/2017	32,147	1,731	N/A	3,935	N/A
3/31/2017	30,818	1,659	N/A	3,725	N/A
12/31/2016	29,471	1,560	N/A	3,585	N/A
9/30/2016	28,908	1,477	N/A	3,449	N/A
6/30/2016	28,415	1,452	N/A	3,409	N/A
3/31/2016	28,158	1,399	N/A	3,132	N/A
12/31/2015	27,626	1,358	N/A	3,327	N/A
9/30/2015	26,889	1,256	N/A	3,041	N/A
6/30/2015	25,927	1,175	N/A	3,086	N/A
3/31/2015	24,502	1,136	N/A	2,976	N/A
12/31/2014	23,231	1,067	N/A	2,585	N/A
9/30/2014	22,010	1,094	N/A	2,449	N/A
6/30/2014	21,077	1,083	N/A	2,123	N/A
3/31/2014	20,653	1,040	N/A	2,016	N/A
12/31/2013	20,331	1,011	N/A	2,320	N/A
9/30/2013	20,440	974	N/A	2,212	N/A
6/30/2013	20,259	952	N/A	2,264	N/A
3/31/2013	19,979	921	N/A	2,359	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: FRE's forecast earnings growth (20.8% per year) is above the savings rate (2.2%).

Earnings vs Market: FRE's earnings (20.8% per year) are forecast to grow faster than the BG market (10.8% per year).

High Growth Earnings: FRE's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: FRE's revenue is expected to decline over the next 3 years (-5.2% per year).

High Growth Revenue: FRE's revenue is forecast to decline over the next 3 years (-5.2% per year).

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: FRE's Return on Equity is forecast to be low in 3 years time (9.1%).

Fresenius SE KGaA Future Growth

Future criteria checks 3/6

Key information

Recent future growth updates

Fresenius SE & Co. KGaA Provides Earnings Guidance for the Year 2022

Recent updates

PAI Mid-Market Fund SCSp. managed by PAI Partners completed the acquisition of 67% stake in Vamed rehabilitation business from Fresenius SE & Co. KGaA (XTRA:FRE).

PAI Mid-Market Fund SCSp. managed by PAI Partners agreed to acquire 67% stake in Vamed rehabilitation business from Fresenius SE & Co. KGaA (XTRA:FRE).

Verme family with other shareholders completed the acquisition of additional 70% stake in Clinica Ricardo Palma S.A. from Fresenius SE & Co. KGaA (XTRA:FRE).

IVIRMA Global SL and GED Iberian Private Equity, S.A., SGEIC completed the acquisition of EUVITRO S.L.U. from Fresenius SE & Co. KGaA (XTRA:FRE).

German Fresenius Reportedly Seeks to Sell Vamed Reha

Fresenius SE & Co. KGaA to Report Fiscal Year 2023 Final Results on Mar 14, 2024

IVIRMA Global SL and GED Iberian Private Equity, S.A., SGEIC agreed to acquire EUVITRO S.L.U. from Fresenius SE & Co. KGaA (XTRA:FRE) for €500 million.

Fresenius SE & Co. KGaA to Report Q2, 2024 Results on Jul 31, 2024

KKR in Talks to Buy Eugin from Fresenius

Fresenius Reportedly Plans to Offload Digital Subsidiary Curalie

New minor risk - Profit margin trend

Fresenius SE & Co. KGaA to Report Q3, 2023 Results on Nov 02, 2023

Fresenius Se & Co. Kgaa Proposes Dividend for 2022

Fresenius SE & Co. KGaA to Report Q1, 2023 Results on May 09, 2023

Fresenius SE & Co. KGaA, Annual General Meeting, May 17, 2023

QIC Reportedly Set to Clinch Healius Day Hospital Unit for $140 Million Plus

Brookfield Reportedly Drops Out of Race to Buy Healius

Fresenius SE Announces Chief Financial Officer Changes

Fresenius SE & Co. KGaA Announces Michael Sen as CEO on October 1, 2022 Succeeding Stephan Sturm

Second quarter 2022 earnings released: EPS: €0.68 (vs €0.84 in 2Q 2021)

Healius Reportedly Launches Day Surgery Sale Process

Fresenius Kabi Introduces Generic Iodixanol Contrast Media Agent

First quarter 2022 earnings released: EPS: €0.74 (vs €0.78 in 1Q 2021)

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment deteriorated over the past week

Fresenius SE & Co. KGaA Provides Earnings Guidance for the Year 2022

Third quarter 2021 earnings released: EPS €0.74 (vs €0.77 in 3Q 2020)

Second quarter 2021 earnings released: EPS €0.84 (vs €0.74 in 2Q 2020)

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies